Osmosis Investment Management UK Ltd Purchases New Holdings in Illumina, Inc. $ILMN

Osmosis Investment Management UK Ltd acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, HoldingsChannel reports. The firm acquired 5,260 shares of the life sciences company’s stock, valued at approximately $925,000.

Several other hedge funds and other institutional investors also recently modified their holdings of ILMN. Elyxium Wealth LLC acquired a new position in shares of Illumina in the fourth quarter valued at approximately $25,000. TD Waterhouse Canada Inc. acquired a new stake in shares of Illumina during the fourth quarter worth $26,000. Laurel Wealth Advisors LLC purchased a new position in Illumina in the 4th quarter valued at $26,000. Activest Wealth Management increased its stake in Illumina by 671.9% in the 4th quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock valued at $32,000 after buying an additional 215 shares during the period. Finally, Keating Financial Advisory Services Inc. acquired a new position in Illumina in the 2nd quarter valued at $32,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ILMN shares. Royal Bank Of Canada raised their target price on shares of Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Evercore reissued an “outperform” rating on shares of Illumina in a report on Monday, July 6th. Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective on the stock in a report on Thursday, May 14th. Finally, JPMorgan Chase & Co. boosted their target price on Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Illumina has a consensus rating of “Hold” and a consensus price target of $188.40.

Illumina Stock Performance

NASDAQ ILMN opened at $223.22 on Tuesday. Illumina, Inc. has a 1-year low of $88.00 and a 1-year high of $223.97. The company has a market capitalization of $33.71 billion, a P/E ratio of 41.65, a PEG ratio of 3.09 and a beta of 1.44. The business has a 50 day moving average price of $189.13 and a 200 day moving average price of $153.14. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.Illumina’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the business earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Sell-side analysts expect that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Insider Buying and Selling at Illumina

In other Illumina news, Director Keith A. Meister sold 299,336 shares of the firm’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $217.96, for a total transaction of $65,243,274.56. Following the completion of the transaction, the director directly owned 1,409,851 shares in the company, valued at approximately $307,291,123.96. This trade represents a 17.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Scott M. Davies sold 615 shares of Illumina stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $200.00, for a total transaction of $123,000.00. Following the transaction, the insider owned 20,338 shares of the company’s stock, valued at approximately $4,067,600. The trade was a 2.94% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 2,095,958 shares of company stock valued at $401,720,974 in the last quarter. Insiders own 2.90% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.